Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response.
Glioblastoma multiforme is the most aggressive primary brain tumor of adults, but lacks reliable and liquid biomarkers. We evaluated circulating plasma transcripts of metastasis-associated in colon cancer-1 (MACC1), a prognostic biomarker for solid cancer entities, for prediction of clinical outcome...
| Published in: | Cancers Vol. 11; no. 6; pp. 825 - 826 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
MDPI
Jun2019
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137456459&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 137456459 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726694 B74B jtl: Cancers issn: 20726694 maglogo: N pubinfo: dt: Jun2019 vid: 11 iid: 6 pid: 97109 pub: MDPI artinfo: ui: 137456459 137456459 137456459 10.3390/cancers11060825 137456459 ppf: 825 ppct: 1 formats: tig: atl: Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response. aug: au: Hagemann, Carsten Neuhaus, Nikolas Dahlmann, Mathias Kessler, Almuth F. Kobelt, Dennis Herrmann, Pia Eyrich, Matthias Freitag, Benjamin Linsenmann, Thomas Monoranu, Camelia M. Ernestus, Ralf-Ingo Löhr, Mario Stein, Ulrike affil: Tumorbiology Laboratory, Department of Neurosurgery, University of Würzburg, Josef-Schneider-Str. 11, D-97080 Würzburg, Germany sug: subj: Colonic Neoplasms Neoplasm Metastasis Transcription Factors Blood Tumor Markers, Biological Blood Glioma Prognosis Glioma Therapy Human Treatment Outcomes Oxidoreductases Mutation Glioma Familial and Genetic ab: Glioblastoma multiforme is the most aggressive primary brain tumor of adults, but lacks reliable and liquid biomarkers. We evaluated circulating plasma transcripts of metastasis-associated in colon cancer-1 (MACC1), a prognostic biomarker for solid cancer entities, for prediction of clinical outcome and therapy response in glioblastomas. MACC1 transcripts were significantly higher in patients compared to controls. Low MACC1 levels clustered together with other prognostically favorable markers. It was associated with patients' prognosis in conjunction with the isocitrate dehydrogenase (IDH) mutation status: IDH1 R132H mutation and low MACC1 was most favorable (median overall survival (OS) not yet reached), IDH1 wildtype and high MACC1 was worst (median OS 8.1 months), while IDH1 wildtype and low MACC1 was intermediate (median OS 9.1 months). No patients displayed IDH1 R132H mutation and high MACC1. Patients with low MACC1 levels receiving standard therapy survived longer (median OS 22.6 months) than patients with high MACC1 levels (median OS 8.1 months). Patients not receiving the standard regimen showed the worst prognosis, independent of MACC1 levels (low: 6.8 months, high: 4.4 months). Addition of circulating MACC1 transcript levels to the existing prognostic workup may improve the accuracy of outcome prediction and help define more precise risk categories of glioblastoma patients. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|